Kohei Kikkawa

1.1k total citations
56 papers, 900 citations indexed

About

Kohei Kikkawa is a scholar working on Molecular Biology, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Kohei Kikkawa has authored 56 papers receiving a total of 900 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 16 papers in Physiology and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Kohei Kikkawa's work include Nitric Oxide and Endothelin Effects (15 papers), Phosphodiesterase function and regulation (15 papers) and Sexual function and dysfunction studies (11 papers). Kohei Kikkawa is often cited by papers focused on Nitric Oxide and Endothelin Effects (15 papers), Phosphodiesterase function and regulation (15 papers) and Sexual function and dysfunction studies (11 papers). Kohei Kikkawa collaborates with scholars based in United States and Japan. Kohei Kikkawa's co-authors include J. Kevin Donahue, Eduardo Marbán, Hirotaka Inoue, Jun Kotera, Kenji Omori, David C. Johns, John H. Lawrence, Hideo Yabana, Koji Yano and T Nagao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Circulation Research.

In The Last Decade

Kohei Kikkawa

53 papers receiving 853 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kohei Kikkawa United States 18 424 285 191 179 137 56 900
David J. Morgans United States 18 500 1.2× 187 0.7× 354 1.9× 19 0.1× 131 1.0× 56 1.3k
G. Kurt Hogaboom United States 18 515 1.2× 95 0.3× 98 0.5× 33 0.2× 434 3.2× 29 1.1k
Loan Miller United States 15 211 0.5× 23 0.1× 173 0.9× 72 0.4× 93 0.7× 23 709
L T Hamel United States 14 268 0.6× 169 0.6× 69 0.4× 28 0.2× 178 1.3× 18 516
Kazumi Kondo Japan 17 575 1.4× 99 0.3× 333 1.7× 25 0.1× 45 0.3× 39 1.3k
Alan D. Robertson United Kingdom 17 405 1.0× 60 0.2× 205 1.1× 86 0.5× 259 1.9× 31 887
Anna Rita Renzetti Italy 16 458 1.1× 75 0.3× 83 0.4× 53 0.3× 150 1.1× 45 739
Roberto Buccafusca United States 14 305 0.7× 56 0.2× 36 0.2× 107 0.6× 66 0.5× 23 710
James C. Hershey United States 13 289 0.7× 55 0.2× 36 0.2× 202 1.1× 168 1.2× 22 685
Joachim C. Burbiel Germany 14 389 0.9× 64 0.2× 144 0.8× 34 0.2× 95 0.7× 20 797

Countries citing papers authored by Kohei Kikkawa

Since Specialization
Citations

This map shows the geographic impact of Kohei Kikkawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kohei Kikkawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kohei Kikkawa more than expected).

Fields of papers citing papers by Kohei Kikkawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kohei Kikkawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kohei Kikkawa. The network helps show where Kohei Kikkawa may publish in the future.

Co-authorship network of co-authors of Kohei Kikkawa

This figure shows the co-authorship network connecting the top 25 collaborators of Kohei Kikkawa. A scholar is included among the top collaborators of Kohei Kikkawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kohei Kikkawa. Kohei Kikkawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sakamoto, Toshiaki, Yuichi Koga, Masataka Hikota, et al.. (2015). 8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(7). 1431–1435. 12 indexed citations
2.
Sakamoto, Toshiaki, Yuichi Koga, Masataka Hikota, et al.. (2014). The discovery of avanafil for the treatment of erectile dysfunction: A novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor. Bioorganic & Medicinal Chemistry Letters. 24(23). 5460–5465. 25 indexed citations
3.
4.
Wang, Run, Arthur L. Burnett, Kenji Omori, et al.. (2012). Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability. The Journal of Sexual Medicine. 9(8). 2122–2129. 53 indexed citations
5.
Ukita, Tatsuzo, Yoshinori Nakamura, Akira Kubo, et al.. (2003). 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(14). 2341–2345. 28 indexed citations
6.
Inoue, Hirotaka, et al.. (2003). T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs. European Journal of Pharmacology. 485(1-3). 283–288. 4 indexed citations
7.
Inoue, Hirotaka, et al.. (2002). Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. European Journal of Pharmacology. 440(1). 45–52. 32 indexed citations
8.
Inoue, Hirotaka, et al.. (2002). T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters. European Journal of Pharmacology. 443(1-3). 179–184. 2 indexed citations
9.
Morimoto, Hiroshi, et al.. (2002). Modifications and structure–activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists. Bioorganic & Medicinal Chemistry Letters. 12(1). 81–84. 10 indexed citations
10.
Inoue, Hirotaka, et al.. (2001). Role of adenosine and P2 receptors in the penile tumescence in anesthetized dogs. European Journal of Pharmacology. 425(1). 51–55. 30 indexed citations
11.
Inoue, Hirotaka, et al.. (2001). T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats. European Journal of Pharmacology. 422(1-3). 109–114. 8 indexed citations
12.
Yano, Koji, et al.. (2001). Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. European Journal of Pharmacology. 411(1-2). 161–168. 26 indexed citations
13.
14.
Noto, Takahisa, et al.. (2000). Potentiation of Penile Tumescence by T-1032, a New Potent and Specific Phosphodiesterase Type V Inhibitor, in Dogs. Journal of Pharmacology and Experimental Therapeutics. 294(3). 870–875. 19 indexed citations
15.
Kikkawa, Kohei, et al.. (1999). Characteristics of heterogeneity in the expression of vasoconstriction in response to NG-monomethyl-l-arginine in isolated canine arteries. European Journal of Pharmacology. 379(2-3). 167–173. 4 indexed citations
16.
Donahue, J. Kevin, et al.. (1998). Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Therapy. 5(5). 630–634. 84 indexed citations
17.
Miyauchi, Takashi, Tsutomu Kobayashi, Satoshi Sakai, et al.. (1998). Cloning of Hamster Preproendothelin-1 cDNA and Its Expression in the Heart. Journal of Cardiovascular Pharmacology. 31. S298–S301. 4 indexed citations
18.
Kikkawa, Kohei, Sakae Murata, Hideo Kurosawa, et al.. (1994). Effect of Clentiazem (TA-3090) with Posttreatment on Neurologic and Histologic Disorders of Stroke-Prone Spontaneously Hypertensive Rats with History of Stroke. Journal of Cardiovascular Pharmacology. 23(1). 166–166. 3 indexed citations
19.
20.
Kikkawa, Kohei, Sakae Murata, & Taku Nagao. (1989). Endothelium‐dependent calcium‐induced relaxation in the presence of Ca2+ ‐antagonists in canine depolarized coronary arteries. British Journal of Pharmacology. 98(2). 700–706. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David J. Morgans Breakdown of academic impact, for papers by G. Kurt Hogaboom Breakdown of academic impact, for papers by Loan Miller Breakdown of academic impact, for papers by L T Hamel Breakdown of academic impact, for papers by Kazumi Kondo Breakdown of academic impact, for papers by Alan D. Robertson Breakdown of academic impact, for papers by Anna Rita Renzetti Breakdown of academic impact, for papers by Roberto Buccafusca Breakdown of academic impact, for papers by James C. Hershey Breakdown of academic impact, for papers by Joachim C. Burbiel
Rankless by CCL
2026